Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium

Francesco Pierconti, Alessandra Cassano, Giovanni Schinzari, Ernesto Rossi, Giovanna Garufi, Santa Monterisi, Antonia Strippoli, Ettore D'Argento, Carlo Antonio Barone

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2 every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.
Original languageEnglish
Pages (from-to)8765-8771
Number of pages7
JournalOncotarget
Volume9
DOIs
Publication statusPublished - 2018

Keywords

  • Oncology
  • Second line
  • Toxicity
  • Transitional cell carcinoma of the urothelium
  • Vinflunine

Fingerprint Dive into the research topics of 'Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium'. Together they form a unique fingerprint.

Cite this